Novo Nordisk's Wegovy Gets EU Regulator Endorsement for Cardiovascular Potential

Dow Jones07-26

By Adria Calatayud

Novo Nordisk said European Union drug regulators support a label expansion for its blockbuster Wegovy drug to reflect its potential to reduce risk of major cardiovascular events including heart attacks in obese or overweight adults.

The Danish pharmaceutical giant said Thursday that it expects an implementation of the label update within around one month following the positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use.

The opinion of the committee, known as CHMP, was based on data from a clinical trial that showed a reduction in the risk of major adverse cardiovascular events in adults with cardiovascular disease who were either overweight or obesity and without diabetes, the company said.

Booming demand Novo Nordisk's Wegovy weight-loss drug has far outstripped supply and sent the Danish firm's valuation soaring to become Europe's most valuable company with a stock market valuation above that of the GDP of Denmark.

Write to Adria Calatayud at adria.calatayud@wsj.com

(END) Dow Jones Newswires

July 25, 2024 12:11 ET (16:11 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2454809521?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-26 00:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2454809521","market":"us","top_or_hot":-1,"title":"Novo Nordisk's Wegovy Gets EU Regulator Endorsement for Cardiovascular Potential","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adria Calatayud \n</p>\n<pre>\n \n</pre>\n<p>\n  Novo Nordisk said European Union drug regulators support a label expansion for its blockbuster Wegovy drug to reflect its potential to reduce risk of major cardiovascular events including heart attacks in obese or overweight adults. \n</p>\n<p>\n  The Danish pharmaceutical giant said Thursday that it expects an implementation of the label update within around one month following the positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use. \n</p>\n<p>\n  The opinion of the committee, known as CHMP, was based on data from a clinical trial that showed a reduction in the risk of major adverse cardiovascular events in adults with cardiovascular disease who were either overweight or obesity and without diabetes, the company said. \n</p>\n<p>\n  Booming demand Novo Nordisk's Wegovy weight-loss drug has far outstripped supply and sent the Danish firm's valuation soaring to become Europe's most valuable company with a stock market valuation above that of the GDP of Denmark. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adria Calatayud at adria.calatayud@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 25, 2024 12:11 ET (16:11 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk's Wegovy Gets EU Regulator Endorsement for Cardiovascular Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk's Wegovy Gets EU Regulator Endorsement for Cardiovascular Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-26 00:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Adria Calatayud \n\n\n \n\n\n  Novo Nordisk said European Union drug regulators support a label expansion for its blockbuster Wegovy drug to reflect its potential to reduce risk of major cardiovascular ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BZ1G4Q59.USD","symbol_name":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2454809521","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2454809521","pubTimestamp":1721923860,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Novo Nordisk said European Union drug regulators support a label expansion for its blockbuster Wegovy drug to reflect its potential to reduce risk of major cardiovascular events including heart attacks in obese or overweight adults.The Danish pharmaceutical giant said Thursday that it expects an implementation of the label update within around one month following the positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use.The opinion of the committee, known as CHMP, was based on data from a clinical trial that showed a reduction in the risk of major adverse cardiovascular events in adults with cardiovascular disease who were either overweight or obesity and without diabetes, the company said.Booming demand Novo Nordisk's Wegovy weight-loss drug has far outstripped supply and sent the Danish firm's valuation soaring to become Europe's most valuable company with a stock market valuation above that of the GDP of Denmark.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4082":"医疗保健设备","CSII":"Cardiovascular Systems","BK4156":"煤与消费用燃料","NVO":"诺和诺德","BK4585":"ETF&股票定投概念","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4588":"碎股","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4007":"制药","BK4532":"文艺复兴科技持仓"},"translate_title":"诺和诺德的Wegovy因其心血管潜力获得欧盟监管机构的认可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSII":1,"NVO":1},"content_text":"By Adria Calatayud \n\n\n \n\n\n  Novo Nordisk said European Union drug regulators support a label expansion for its blockbuster Wegovy drug to reflect its potential to reduce risk of major cardiovascular events including heart attacks in obese or overweight adults. \n\n\n  The Danish pharmaceutical giant said Thursday that it expects an implementation of the label update within around one month following the positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use. \n\n\n  The opinion of the committee, known as CHMP, was based on data from a clinical trial that showed a reduction in the risk of major adverse cardiovascular events in adults with cardiovascular disease who were either overweight or obesity and without diabetes, the company said. \n\n\n  Booming demand Novo Nordisk's Wegovy weight-loss drug has far outstripped supply and sent the Danish firm's valuation soaring to become Europe's most valuable company with a stock market valuation above that of the GDP of Denmark. \n\n\n \n\n\n  Write to Adria Calatayud at adria.calatayud@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 25, 2024 12:11 ET (16:11 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Policy And Regulatory","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.26.3","shortVersion":"4.26.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2454809521"}